Amgen

Gilead Sciences

Vertex Pharmaceuticals

Regeneron Pharmaceuticals

IQVIA Hlds

Illumina

Natera

Biogen

ICON

Alnylam Pharmaceuticals

VanEck Vectors Biotech ETF

BBH tracks a market-cap-weighted index of the 25 largest biotech firms globally.

iShares U.S. Home Construction ETF

VanEck Vectors Retail ETF

Invesco S&P 500 Enhanced Value ETF

SPDR S&P Aerospace & Defense ETF

Communication Services Select Sector SPDR Fund

Despite the age-old trend of a Santa rally, 2018 was a massive downer. Since 2019 is giving the same cues, investors can seek refuge in these safer ETFs.

Not Santa, Trade Will Rule This December: ETFs to Your Rescue

ARK Genomic Revolution Multi-Sector ETF

Virtus LifeSci Biotech Products ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

First Trust NYSE Arca Biotechnology Index Fund

iShares Nasdaq Biotechnology ETF

Invesco Dynamic Biotechnology & Genome ETF

ALPS Medical Breakthroughs ETF

SPDR S&P Biotech ETF

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

A Guide to Biotech ETF Investing

CRISPR Therapeutics

Global Blood Therapeutics

Novartis

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.

Why Biotech ETFs Surged in Monday's Trading Session

iShares International Dividend Growth ETF

Invesco KBW High Dividend Yield Financial ETF

Alpha Architect US Quantitative Momentum ETF

Materials Select Sector SPDR Fund

The global market has been rallying hard since October. Investors can thus bet on these high-flying ETFs.

Risk-On Sentiments Are Back: ETFs to Play

Biotechnology company Amgen (NasdaqGS: AMGN) is throwing $2.7 billion into BeiGene (NasdaqGS: BGNE), sending the Chinese biotech’s shares surging and bolstering sector-related ETFs. Among the top performers on Friday, the Loncar Cancer Immunotheraphy ETF (NasdaqGM: CNCR) increased 3.2% and the VanEck Vectors Biotech ETF (BBH) advanced 2.7%.

Biotech ETFs Strengthen as Amgen Invests in China’s BeiGene

Amid intensifying scrutiny of drug pricing and other political pressures, biotechnology ETFs and active mutual funds endured some rough sledding in the third quarter. The iShares Nasdaq Biotechnology ETF (IBB), VanEck Vectors Biotech ETF (BBH) and the equal-weight SPDR S&P Biotech ETF (XBI) are all saddled with third-quarter losses and data suggest investors have been fleeing [.

Biotech ETFs Had A Rough Third Quarter

iShares Evolved U.S. Innovative Healthcare ETF

Invesco Dynamic Pharmaceuticals ETF

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

Amgen to Buy Celgene's Otezla: 5 ETF Drugs

Bristol-Myers

Celgene

Direxion Daily S&P Biotech Bull 3X Shares

When the stock market is hitting record highs, it’s important to remember that it’s really a market of stocks rather than a stock market. Not all companies are created equal. Nor are all sectors.

Top Biotech Stocks and ETFs: A Sector in Trouble or a Huge Bargain

iShares U.S. Healthcare ETF

Vanguard Health Care ETF

M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.

Health Day Checkup of Medical ETFs: 5 Top Picks

News for VanEck Vectors Biotech ETF ETF (BBH)